TRUQAP 160 mg film-coated tablets, Fulvestrant Dr. Reddy’s 250 mg Solution For Injection in Pre-Filled Syringe, RLY-2608, Fulvestrant EVER Pharma 250 mg solution for injection in pre-filled syringe, Fulvestrant Dr. Reddys 250 mg solución inyectable en jeringa precargada EFG, TRUQAP 200 mg film-coated tablets
RLY-2608-102
Phase 3 small_molecule active
Quick answer
TRUQAP 160 mg film-coated tablets, Fulvestrant Dr. Reddy’s 250 mg Solution For Injection in Pre-Filled Syringe, RLY-2608, Fulvestrant EVER Pharma 250 mg solution for injection in pre-filled syringe, Fulvestrant Dr. Reddys 250 mg solución inyectable en jeringa precargada EFG, TRUQAP 200 mg film-coated tablets for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer is a Phase 3 program (small_molecule) at Relay Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Relay Therapeutics
- Indication
- PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active